Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu AG09222 with ubrogepant in migraine
NCT06578585Phase 1Completed
- Sponsor
- Lundbeck
- Start
- Sep 2024
- Primary completion
- Jul 2025
- Modality
- IgG Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in migraine comparing Ubrogepant with Lu AG09222 with Ubrogepant with Placebo (2 arms). Primary endpoint: Treatment-Emergent Adverse Events at 92 days. Started Sep 2024; status: completed.
02
Drugs
lu ag09222
03
Conditions
migraine
Beyond the preview
Go deeper on NCT06578585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06578585.